From NuGOwiki
The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB
| Taxonomy Navigation Box; search by |
|
All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein |
| 13,14-Dihydro-15-keto-PGE2 | |
|---|---|
 | |
| Chemical Name | (E)-7-[(1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid |
| Chemical Formula | C20H32O5 |
| CAS Number | 363-23-5 |
| Chemical Information | HMDB02776 |
| Biochemical Taxonomy |
|
| Functional Taxonomy | Not Available |
| Nutritional Taxonomy | Not Available |
| Metabolic Pathways | Not Available |
| Biofluid Location |
|
| Tissue Location | Not Available |
| Normal Biofluid Concentrations |
|
| Normal Tissue Concentrations | Not Available |
| Diseases / Conditions Related to Nutrition | Not Available |
| Other (Monogenic Disorders) | Not Available |
| Abnormal Biofluid Concentrations | Not Available |
| Abnormal Tissue Concentrations | Not Available |
| Physiological Processes | Not Available |
| Authors: | |
| Affiliations: |
Contents |
Introduction
guidelines
13,14-dihydro-15-keto-PGE2 is one of the prostaglandin E2 metabolites. (PMID 7190512) Human fetal lung in vitro has the competence to self-differentiate, as early as 12 weeks gestation and presence of high levels in fetal lung of the inactive metabolite 13,14-dihydro-15-keto-PGE2 relative to PGE2 suggests that active prostaglandin catabolism may be one of the mechanisms to retard this stage of maturation in vivo by limiting PGE2 availability. (PMID 8835315)
Biological Function
Catabolism
Diseases / Conditions Related to Nutrition
Other (Monogenic) Disorders